[1] Laboratory of tumor viruses of cancer institute, laboratory of tumor viruses of institute of epidemiology, department of radiotherapy of cancer institute, laboratory of cell biology of cancer institute. Establishment of an epitheloid cell line and a fusiform cell line from a patient with nasopharyngeal carcinoma. Sci Sin, 1978; 21, 127−34.
[2] Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma. Lancet, 2016; 387, 1012−24. doi:  10.1016/S0140-6736(15)00055-0
[3] Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol, 1988; 69, 1051−65. doi:  10.1099/0022-1317-69-5-1051
[4] Lee SP, Tierney RJ, Thomas WA, et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol, 1997; 158, 3325−34.
[5] Pan Y, Zhang J, Zhou L, et al. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochem Biophys Res Commun, 2006; 347, 551−7. doi:  10.1016/j.bbrc.2006.05.214
[6] Wang Z, Yang S, Zhou L, et al. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination. Sci China Life Sci, 2011; 54, 263−6. doi:  10.1007/s11427-011-4147-0
[7] Mo WN, Tang AZ, Zhou L, et al. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Chin Med J (Engl), 2009; 122, 1173−8.
[8] Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 1997; 90, 3245−87. doi:  10.1182/blood.V90.9.3245
[9] Knight SC, Stagg AJ. Antigen-presenting cell types. Curr Opin Immunol, 1993; 5, 374−82. doi:  10.1016/0952-7915(93)90056-X
[10] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 1991; 271−96.
[11] Meixlsperger S, Leung CS, Rämer PC, et al. CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood, 2013; 121, 5034−44. doi:  10.1182/blood-2012-12-473413
[12] Schlitzer A, McGovern N, Teo P, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity, 2013; 38, 970−83. doi:  10.1016/j.immuni.2013.04.011
[13] Zeng Y. Serological massive surveys and vaccines for controlling nasopharygeal carcinoma. 7th Annual Global Virus Networks Meeting 2015, May, 17. www.gvn.org/events/gvn-meetings/.
[14] Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res, 2017; 27, 74−95. doi:  10.1038/cr.2016.157
[15] Zhou ZX, Li D, Guan SS, et al. Immunotherapeutic effects of dendritic cells pulsed with a coden-optimized HPV 16 E6 and E7 fusion gene in vivo and in vitro. Asian Pac J Cancer Prev, 2015; 16, 3843−7. doi:  10.7314/APJCP.2015.16.9.3843
[16] Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer, 2012; 12, 265−77. doi:  10.1038/nrc3258
[17] Verdijk P, Aarntzen EH, Lesterhuis WJ, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res, 2009; 15, 2531−40. doi:  10.1158/1078-0432.CCR-08-2729
[18] Prince HM, Wall DM, Ritchie D, et al. In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunother, 2008; 31, 166−79. doi:  10.1097/CJI.0b013e31815c5153
[19] Zuo JM, Zhou L, Chen ZJ, et al. Induction of cytotoxic T lymphocyte responses in vivo after immunotherapy with dendritic cells in patients with nasopharyngeal carcinoma. J.Microbiol immunol, 2006; 4, 41−8.
[20] Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med, 2004; 350, 2461−70. doi:  10.1056/NEJMoa032260
[21] Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res, 2000; 60, 6878−81.